Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
124.98
+2.58 (2.11%)
NASDAQ · Last Trade: Jul 10th, 11:21 PM EDT
Detailed Quote
Previous Close
122.40
Open
121.50
Bid
100.00
Ask
128.50
Day's Range
121.25 - 126.23
52 Week Range
90.29 - 129.90
Volume
183,378
Market Cap
2.08B
PE Ratio (TTM)
-17.46
EPS (TTM)
-7.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
144,556
Chart
About Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
Ligand Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapies and treatments by leveraging its proprietary drug discovery technologies and a diverse portfolio of drug candidates. The company primarily collaborates with other pharmaceutical and biotechnology firms to discover and advance new medications, particularly in areas such as oncology, cardiovascular diseases, and metabolic disorders. Through its unique platform, Ligand aims to enhance drug efficacy and streamline the development process, contributing to the advancement of healthcare solutions that improve patient outcomes. Read More
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 at 2:40 p.m. Eastern Time.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and other members of the senior management team who will provide an in-depth review of the company’s growth strategy, portfolio, platform technologies, and long-term financial outlook.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss this announcement and answer questions.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs
